Indian Pharma Navigates 2025: Crisis, US Trade Heat, R&D Drive Shape Future

• BSE Healthcare Index underperformed Sensex in 2025, declining 1.5% vs. Sensex's 8.36% gain, due to sector-specific pressures.
• Trump administration threatened 25% tariffs on Indian pharma exports to the US, but generics were ultimately exempted to avoid inflation.
• Cough syrup contamination led to 20 child fatalities, prompting a regulatory overhaul, OTC removal, and tightened manufacturing protocols.
• Glenmark secured a $700M upfront deal with AbbVie for its oncology candidate ISB-2001, potentially reaching $1.2B, marking a major R&D breakthrough.
• Wockhardt's Zaynich became the first Indian NCE NDA accepted by USFDA for review, receiving Fast Track designation for drug-resistant infections.

Why It Matters: Indian pharma navigated 2025 crises, trade heat, and R&D breakthroughs, rebalancing for future growth.